Skip to main content
. 2018 Feb 1;9(13):11258–11267. doi: 10.18632/oncotarget.24371

Figure 6.

Figure 6

(A–C) Protein and mRNA expression levels of Nr4a2 were significantly decreased after treatment with Nr4a2-siRNA in CD4+ T cells from healthy control subjects (p < 0.001, p < 0.001, respectively). (D) mRNA expression levels of GATA3, IL-4, and IL-13 were significantly elevated after treatment with Nr4a2-siRNA in CD4+ T cells from healthy control subjects (p = 0.01, p < 0.001, p < 0.001, respectively). (*p < 0.05, **p < 0.01, ***p < 0.001).